• Search
  • Login
  • Register
Menu
  • Last issue
  • Home
  • News
  • CongressUpdate
  • Specials
  • Guidelines
  • Links
All
  • All
  • BJMO articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here
Journal issues > Issue 7, November 2024 > INTRODUCTION

INTRODUCTION

INTRODUCTION

By: Jacques De Greve MD, PhD

  • Summary
  • Full text
  • Figures
  • PDF

Press play button to have the text read to you.

DEAR COLLEAGUES,

The first Review in this BJMO issue updates the molecular profiling of non-small cell lung cancer (NSCLC) and highlights the role of targeted therapies in locoregional lung cancer. It implies that next-generation sequencing (NGS) should be utilised early in the treatment process to inform therapeutic decisions, which could apply to various cancers. Baseline NGS offers insights into immediate or second-line treatment options and clinical trial eligibility in case of disease progression. It avoids scrambling for tissue for last-minute NGS when a patient progresses and avoids using targeted therapies only as a last resort. However, restrictive reimbursement policies hinder the broader application of NGS, particularly in early-stage cancers. At the same time, the cost of comprehensive genomic profiling (CGP) is relatively low—only a few hundred euros—compared to the expense of treatments. With only the reimbursement of panels of only a few genes, the RIZIV/INAMI can be perceived as short sighted.

The second Review focuses on managing castration-resistant prostate cancer, discussing how different treatment modalities can be tailored to fit individual patient profiles and preferences.

A third Review explores the surprising possibility for cancer patients who are considered cured to still serve as organ donors, detailing the selection criteria involved.

Clinical practice guidelines for rectal cancer stress the importance of testing every rectal tumour for dMMR/MSI-H at diagnosis. The paper quotes, “Nevertheless, every rectal tumor should be tested for dMMR/MSI-H at diagnosis, and an option for neoadjuvant checkpoint inhibition should be offered,” highlighting the significant impact this can have on treatment morbidity. The rarity of this profile (only 1% of patients) should not be a reason to deny these patients access to beneficial options. Thus, some patients can avoid all other treatment modalities and their morbidities.

The Oncocase introduces a rare but severe triad of immune checkpoint inhibitor toxicities known as Triple M Syndrome: myocarditis, myositis, and myasthenia gravis, which can manifest after just one cycle of therapy. Awareness and prompt intervention are crucial.

It should not be confused with the genetic 3-M syndrome.

Lastly, the editor highlights topics at the World Conference on Lung Cancer (WCLC) in San Diego in 2024.

Reimbursement news is the approval of durvalumab for first-line therapy in advanced or recurrent endometrial cancer.

Looking ahead, you are invited to the 18th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice on November 29–30, 2024, in Brussels and to the BSMO Annual Meeting on January 31 and February 1, 2025, in Bruges.

Yours sincerely,

Jacques De Greve, MD, PhD

Editor-in-Chief

Back to index

PDF

11-2024-jacques-de-greve-md-phd-pdf

About authors

Top

Questions or Remarks?

Let us know
  • About BJMO
  • Ads & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJMO is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJMO 2025

Manage Cookie Consent

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}